CFSAN runs lean operation
This article was originally published in The Tan Sheet
Executive Summary
The laboratory infrastructure within FDA's Center for Food Safety and Applied Nutrition has minimal administrative support and little flexibility, according to an interim report on research review presented by an FDA Science Board subcommittee. "There's not as much of a support system within CFSAN," said subcommittee member Rhona Applebaum during the Feb. 22 Science Board meeting in Bethesda, Md. "Oftentimes what we saw and what we heard is, we're asking our chefs to be also the chief cooks and bottle washers." Applebaum, VP and chief scientific and regulatory officer for Coca-Cola, added that the food center is stretched thin performing crucial tasks to protect public health. The subcommittee will continue reviewing CFSAN activities and present its final report at a May 17 Science Board meeting. The Obama administration proposed a 32.9 percent increase to $1.04 billion in FDA food program funding for fiscal 2011 (1"The Tan Sheet" Feb. 8, 2010)
You may also be interested in...
Final CFSAN review at Science Board
FDA's Science Board on Aug. 16 will discuss a subcommittee's final report on the Center for Food Safety and Applied Nutrition's research, a June 29 Federal Register 1notice says. The subcommittee's interim report, presented in February, said CFSAN's laboratory infrastructure has minimal administrative support and little flexibility (2"The Tan Sheet" March 1, 2010, In Brief). The subcommittee began the review in August 2009 and will review intramural research in each FDA center. The Center for Drug Evaluation and Research is next, and the board will discuss an interim report from the CDER subcommittee at the meeting in Bethesda, Md
FDA Budget Request Shows Optimism For Broad Food Safety User Fees
FDA's fiscal 2011 budget request is the latest nudge to Congress that the agency prefers food safety legislation with both expansive and targeted user fees over targeted fees alone
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.